 Biocept Inc NASDAQ:BIOC FRA:B003 reports that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples. These test samples are processed using Biocepts RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego. 